Given the high number of in situ recurrences in HER2-positive DCIS treated with lumpectomy alone, and given its excellent response to irradiation, it seems desirable to offer radiotherapy to all HER2-positive DCIS patients treated with breast-conserving surgery, to optimize local control. Here, ERBB2 is linked to ductal breast carcinoma in situ.